February 10, 2025
Neuro
Stroke Detection Innovator Wellumio Enrolls First Patient in Australian Clinical Trial for ‘Axana’ 0.1T portable magnetic resonance imaging device (Portable MRI study)
“Revolutionary portable device leverages advanced magnetic resonance technology to rapidly detect acute stroke biomarkers, enabling frontline care teams to make faster, life-saving decisions within the critical ‘golden hour.” A Melbourne hospital images the first patient in Australia…
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint.
RapidAI Reveals Superiority Over Competition in LVO Detection – 33% More Cases Identified Than Leading Competitor, Alongside Numerous Abstracts at ISC 2025
SAN MATEO, Calif.–(BUSINESS WIRE)–The numbers speak for themselves, RapidAI’s deep clinical AI is delivering results where competitors are falling short. New data from the largest head-to-head study to date proves RapidAI’s LVO detection outperforms Viz.ai by a staggering 33%, detecting far more stroke cases and reducing the risk of missed […]
Revalesio Announces New Analyses from Phase 2 RESCUE Study of RNS60 in Patients with Acute Ischemic Stroke in Oral Presentation at the International Stroke Conference 2025
Lowering of infarct growth – brain tissue loss – by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient’s recovery TACOMA, Wash.,…
Vivistim Paired VNS Therapy Outcomes & Success at Comprehensive Stroke Centers Highlighted at ISC 2025
Dr. Ronald Benitez to present Vivistim safety and outcomes data for the largest cohort of ischemic stroke survivors AUSTIN, Texas and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ — Dr. Ronald P. Benitez, a neurosurgeon at Atlantic Brain and Spine, will present safety and outcomes data from the…
Terumo Neuro Showcases Fully Integrated, Comprehensive Stroke Portfolio at International Stroke Conference Delivering Groundbreaking Innovation from Access to Revascularization
Terumo Neuro Also Features Much-Anticipated SOFIA™ 88 Neurovascular Support Catheter Showcased at ISC Symposium led by Dr. Ameer E. Hassan on Thursday, February 6th ALISO VIEJO, Calif. and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ — Terumo Neuro, a global neurovascular company and wholly…
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract research organization (“CRO”) for the Company’s upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Validcare is a leading U.S. based full service CRO with experience across a wide range of therapeutic indications.
New Data Presented at the International Stroke Conference Further Validates Treatment Impact of Brainomix 360
• This latest research builds upon the growing body of evidence demonstrating the unique impact of Brainomix’s AI-powered software to expand access to life-changing stroke treatments across networks OXFORD, England and CHICAGO, Feb. 4, 2025 /PRNewswire/ — Brainomix, an award-winning…
RapidAI Secures FDA 510(k) Clearance for Groundbreaking AI 3D Head and Neck CTA Imaging: Lumina 3D™
SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in AI-driven medical imaging analysis and coordinated care, has received FDA 510(k) clearance for Lumina 3D™ by RapidAI—an industry-first, automated 3D imaging reconstruction solution designed to replace manual workflows with an AI-powered approach based on the latest groundbreaking AI technology advances. “Obtaining high-quality […]
Recent
Popular
- No commented posts yet